Fighting AMD: the power of nutrition

Article

With a greater understanding of how ocular nutrition affects sight, ophthalmologists need to encourage healthy diets with nutrients and antioxidants essential for healthy vision.

The National Eye Institute's (NEI) first Age-Related Eye Disease Study (AREDS) in 2008 demonstrated that oral supplementation with antioxidant vitamins C and E, beta-carotene and zinc reduced risk of progression to advanced AMD by 25% in high-risk patients.2,3

The 2013 AREDS2 follow-up study found that long-term use (10 years) of the high-dose antioxidant-plus-zinc formula reduced the risk of developing advanced AMD by 34%.

The NEI chose a brand lutein product (Flora-GLO Lutein, Kemin Health/DSM) for the study because it is the only purified lutein that is the same as the lutein molecule found in nature.

Participants who took the AREDS formulation with lutein and zeaxanthin had an 18% reduced risk of developing advanced AMD over the 5-year study. Participants who had low levels and intake of lutein and zeaxanthin before the study began were 25% less likely to develop advanced AMD compared with participants with similar dietary intake who were not taking lutein and zeaxanthin supplements.4

The power of patient education

For best eye health, older adults and those at risk of vision loss due to AMD should take vitamins containing 10 mg of lutein and 2 mg of zeaxanthin. Yet, few people are getting the lutein and zeaxanthin they need. According to the National Health and Nutrition Examination Survey in the US, a mere 41% of Americans are familiar with lutein, and only 6% have ever heard of zeaxanthin.5

Encouraging diets that contain essential nutrients and antioxidants for healthy vision - and recommending supplements for nutrients like vitamin E, lutein and zeaxanthin where diet alone does not meet daily recommendations - is crucial to the sustained health of eye care patients globally.

References

1. S. Resnikoff et al., Bull. World Health Organ., 2004;82(11):844–851.

2. http://www.nei.nih.gov/news/pressreleases/101201.asp

3. http://www.ncbi.nlm.nih.gov/pubmed/11594942

4. http://www.nei.nih.gov/news/pressreleases/050513.asp

5. NHANES 2003–2008.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.